𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phenotype of bone metastases of nonsmall cell lung cancer: Epidermal growth factor receptor expression and KRAS mutational status

✍ Scribed by Gayane Badalian; Tamás Barbai; Erzsébet Rásó; Katalin Derecskei; Miklós Szendrői; József Tímár

Book ID
105644949
Publisher
Springer Netherlands
Year
2007
Tongue
English
Weight
667 KB
Volume
13
Category
Article
ISSN
1219-4956

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expression of epidermal growth factor re
Expression of epidermal growth factor receptor in urinary bladder cancer metastases
✍ Peter Bue; Kenneth Wester; Anna Sjöström; Anders Holmberg; Sten Nilsson; Jörgen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 518 KB

Bladder cancers frequently exhibit an increased number of epidermal growth factor receptors (EGFR) in comparison to normal urothelium. The EGFR could potentially be a target for toxic conjugates. The aim of our study was to compare the expression of EGFR in metastases with concurrent or primary tumo

Expression of epidermal growth factor re
Expression of epidermal growth factor receptors in four histologic cell types of lung cancer
✍ Shizuka Kaseda; Masakazu Ueda; Soji Ozawa; Tsuneo Ishihara; Osahiko Abe; Nobuyos 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB

Lung cancer tissues from 68 patients were examined for epidermal growth factor (EGF) receptor levels and EGF receptor gene copy numbers. Histologic cell types of these lung cancer tissues included squamous-cell carcinoma (n = 30), adenocarcinoma (n = 28), large-cell carcinoma (n = 4), and small-cell

Response to dual blockade of epidermal g
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor
✍ Shirish M. Gadgeel; Shadan Ali; Philip A. Philip; Fakhara Ahmed; Antoinette Wozn 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB 👁 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC), particularly those with tumors that have EGFR‐TK domain mutations. Moreover, the EGFR and cyclooxygenase (COX)‐2